Catriona Yale is Chief Development Officer at Akero Therapeutics, Inc. (AKRO). They have made 19 open-market trades across 1 company since 2021, most recently 2025-12-09.
CIK 0001779308
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 19 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKRO | 74,800 | $4.1M |
Shares reported on the most recent Form 4, priced at the 2025-11-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKRO | SELL | 2025-09-11 | 2025-09-12 | $43.02 | $28K | +9.8% | +24.1% | N/A |
| AKRO | SELL · 10b5-1 | 2025-07-16 | 2025-07-18 | $52.95 | $1.1M | -7.9% | -6.2% | +3.6% |
| AKRO | SELL | 2025-06-18 | 2025-06-20 | $54.84 | $179K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL · 10b5-1 | 2025-06-16 | 2025-06-20 | $54.06 | $876K | -3.3% | -4.2% | -13.9% |
| AKRO | SELL | 2025-06-10 | 2025-06-12 | $54.00 | $151K | +5.5% | +1.0% | -17.1% |
| AKRO | SELL · 10b5-1 | 2025-05-15 | 2025-05-19 | $39.30 | $786K | +28.8% | +42.4% | +26.0% |
| AKRO | SELL · 10b5-1 | 2025-04-15 | 2025-04-16 | $37.86 | $642K | +16.0% | +4.8% | +39.6% |
| AKRO | SELL · 10b5-1 | 2025-03-17 | 2025-03-18 | $44.76 | $895K | -0.9% | -12.7% | +29.3% |
| AKRO | SELL | 2025-03-12 | 2025-03-14 | $44.88 | $28K | -1.9% | -14.8% | +21.3% |
| AKRO | SELL · 10b5-1 | 2025-02-18 | 2025-02-21 | $49.87 | $499K | -12.9% | -13.0% | -5.5% |
| AKRO | SELL · 10b5-1 | 2025-01-27 | 2025-01-31 | $56.45 | $5.1M | -8.1% | -15.3% | -15.7% |
| AKRO | SELL · 10b5-1 | 2025-01-27 | 2025-01-31 | $55.59 | $5.0M | -8.1% | -15.3% | -15.7% |
| AKRO | SELL · 10b5-1 | 2024-12-16 | 2024-12-18 | $29.11 | $528K | -2.7% | -12.1% | +52.3% |
| AKRO | SELL | 2024-12-10 | 2024-12-12 | $30.79 | $173K | +0.0% | -20.7% | +60.6% |
| AKRO | SELL · 10b5-1 | 2024-11-15 | 2024-11-19 | $27.71 | $494K | +4.2% | -7.6% | +60.9% |
| AKRO | SELL · 10b5-1 | 2024-11-06 | 2024-11-08 | $35.19 | $352K | -11.9% | -10.5% | +58.0% |
| AKRO | SELL · 10b5-1 | 2024-10-30 | 2024-11-01 | $32.60 | $1.3M | -3.8% | -0.6% | +71.9% |
| AKRO | SELL · 10b5-1 | 2024-10-14 | 2024-10-16 | $30.36 | $1.3M | -4.3% | -9.5% | -29.5% |
| AKRO | SELL · 10b5-1 | 2024-09-20 | 2024-09-23 | $27.65 | $152K | -2.5% | +1.1% | +0.0% |
| AKRO | SELL · 10b5-1 | 2024-09-16 | 2024-09-18 | $27.55 | $462K | +2.5% | +11.5% | +9.3% |
| AKRO | SELL | 2024-09-10 | 2024-09-13 | $26.18 | $17K | +2.2% | +9.5% | +5.9% |
| AKRO | SELL · 10b5-1 | 2024-09-03 | 2024-09-05 | $27.61 | $26K | +0.3% | +0.7% | +16.4% |
| AKRO | SELL · 10b5-1 | 2024-08-23 | 2024-08-28 | $27.53 | $630K | -4.6% | +4.7% | +15.5% |
| AKRO | SELL | 2024-06-11 | 2024-06-13 | $22.64 | $64K | -5.2% | +13.4% | +5.9% |
| AKRO | SELL | 2024-03-13 | 2024-03-15 | $28.33 | $20K | -9.3% | -19.4% | -8.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.